Hubei Biocause Pharmaceutical announced that it plans to repurchase company shares worth 50-100 million yuan, with a repurchase price not exceeding 3.34 yuan/share. The repurchased shares will be used for cancellation to reduce the registered capital of the company.
天茂集团：拟5000万-1亿元回购股份并注销
Hubei Biocause Pharmaceutical: plans to repurchase shares totaling 50-100 million yuan and cancel them.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.